Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside

Abstract

Immunological risk stratification has a central role in determining both the feasibility of solid organ transplantation and the type (and amount) of induction and maintenance immunosuppressive therapy. Currently there is poor consensus on how to exactly estimate the global immunological risk, and most transplant centers adopt complicated internal guidelines for risk stratification. Here we systematically review published evidences that should drive appropriateness in risk stratification, focusing on donor-specific antibodies against HLA and other antigens.

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

“…The bedside-to-bench approach starts from a target already proven to be relevant in patients and requires animal models that are suitable to explain the pathological mechanisms. 58 , 59 Comparative transcriptome analysis may help to match human and rodent disease. 60 This approach may also include transgenic models that have little to do with human disease but help to identify the molecular or cellular biology behind the clinical finding.…”